These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 26902117)
1. Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo. Du M; Wang Q; Li W; Ma X; Wu L; Guo F; Zhao S; Huang F; Wang H; Qin G Biochem Biophys Res Commun; 2016 Mar; 471(4):416-22. PubMed ID: 26902117 [TBL] [Abstract][Full Text] [Related]
2. Emodin ameliorates high glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo. Chen T; Zheng LY; Xiao W; Gui D; Wang X; Wang N Cell Physiol Biochem; 2015; 35(4):1425-36. PubMed ID: 25791065 [TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy. Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631 [TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats. Chen J; Chen Y; Luo Y; Gui D; Huang J; He D Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932 [TBL] [Abstract][Full Text] [Related]
5. The roles of connective tissue growth factor and integrin-linked kinase in high glucose-induced phenotypic alterations of podocytes. Dai HY; Zheng M; Lv LL; Tang RN; Ma KL; Liu D; Wu M; Liu BC J Cell Biochem; 2012 Jan; 113(1):293-301. PubMed ID: 21913214 [TBL] [Abstract][Full Text] [Related]
6. Jixuepaidu Tang-1 inhibits epithelial-mesenchymal transition and alleviates renal damage in DN mice through suppressing long non-coding RNA LOC498759. Jin J; Zhang Z; Chen J; Liu Y; Chen Q; Wang Q Cell Cycle; 2019 Nov; 18(22):3125-3136. PubMed ID: 31564202 [TBL] [Abstract][Full Text] [Related]
7. Effects of overexpressing FoxO1 on apoptosis in glomeruli of diabetic mice and in podocytes cultured in high glucose medium. Li W; Wang Q; Du M; Ma X; Wu L; Guo F; Zhao S; Huang F; Wang H; Qin G Biochem Biophys Res Commun; 2016 Sep; 478(2):612-7. PubMed ID: 27475499 [TBL] [Abstract][Full Text] [Related]
8. High glucose increases Cdk5 activity in podocytes via transforming growth factor-β1 signaling pathway. Zhang Y; Li H; Hao J; Zhou Y; Liu W Exp Cell Res; 2014 Aug; 326(2):219-29. PubMed ID: 24768698 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kang YS; Li Y; Dai C; Kiss LP; Wu C; Liu Y Kidney Int; 2010 Aug; 78(4):363-73. PubMed ID: 20505657 [TBL] [Abstract][Full Text] [Related]
10. Effects of FoxO1 on podocyte injury in diabetic rats. Guo F; Zhang Y; Wang Q; Ren L; Zhou Y; Ma X; Wu L; Qin G Biochem Biophys Res Commun; 2015 Oct; 466(2):260-6. PubMed ID: 26361145 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of high mobility group box 1 (HMGB1) attenuates podocyte apoptosis and epithelial-mesenchymal transition by regulating autophagy flux. Jin J; Gong J; Zhao L; Zhang H; He Q; Jiang X J Diabetes; 2019 Oct; 11(10):826-836. PubMed ID: 30864227 [TBL] [Abstract][Full Text] [Related]
12. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Wang JY; Gao YB; Zhang N; Zou DW; Wang P; Zhu ZY; Li JY; Zhou SN; Wang SC; Wang YY; Yang JK Mol Cell Endocrinol; 2014 Jul; 392(1-2):163-72. PubMed ID: 24887517 [TBL] [Abstract][Full Text] [Related]
13. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes. Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993 [TBL] [Abstract][Full Text] [Related]
14. Critical role of serum response factor in podocyte epithelial-mesenchymal transition of diabetic nephropathy. Zhao L; Wang X; Sun L; Nie H; Liu X; Chen Z; Guan G Diab Vasc Dis Res; 2016 Jan; 13(1):81-92. PubMed ID: 26408645 [TBL] [Abstract][Full Text] [Related]
15. Triptolide Alleviates Podocyte Epithelial-Mesenchymal Transition via Kindlin-2 and EMT-Related TGF-β/Smad Signaling Pathway in Diabetic Kidney Disease. Ren L; Wan R; Chen Z; Huo L; Zhu M; Yang Y; Chen Q; Zhang X; Wang X Appl Biochem Biotechnol; 2022 Feb; 194(2):1000-1012. PubMed ID: 34596829 [TBL] [Abstract][Full Text] [Related]
16. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation. Liu L; Wang Y; Yan R; Liang L; Zhou X; Liu H; Zhang X; Mao Y; Peng W; Xiao Y; Zhang F; Liu L; Shi M; Guo B Life Sci; 2019 Dec; 238():116957. PubMed ID: 31655195 [TBL] [Abstract][Full Text] [Related]
17. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition. Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212 [TBL] [Abstract][Full Text] [Related]
18. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis. Wang J; Shen L; Hong H; Li J; Wang H; Li X Eur J Pharmacol; 2019 Jun; 852():142-150. PubMed ID: 30876973 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of the FoxO1 Ameliorates Mesangial Cell Dysfunction in Male Diabetic Rats. Qin G; Zhou Y; Guo F; Ren L; Wu L; Zhang Y; Ma X; Wang Q Mol Endocrinol; 2015 Jul; 29(7):1080-91. PubMed ID: 26029993 [TBL] [Abstract][Full Text] [Related]
20. C-peptide ameliorates high glucose-induced podocyte dysfunction through the regulation of the Notch and TGF-β signaling pathways. Luo J; Jiang J; Huang H; Jiang F; Xu Z; Zhou Z; Zhu H Peptides; 2021 Aug; 142():170557. PubMed ID: 33901627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]